The Indian biotech sector faced a major turn of events when Daiichi Sankyo, Japanese firm whose hide and seek with Indian drug company Ranbaxy came to an end as it decided to sell off its entire holding of Sun Pharmaceutical Industries and exit Indian pharma sector after a struggle of eight years. Why it had to offload Ranbaxy and what is in store with the company’s future businesses, find out in Biotecnika magazine’s May 2015 issue.